Charles Schwab’s Matinas BioPharma MTNB Stock Holding History

Charles Schwab’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,568	Closed	-$28.2K	–	3606
2023 Q2	$28.2K	Hold	1,568	–	–	﹤0.01%	3515
2023 Q1	$36.8K	Hold	1,568	–	–	﹤0.01%	3405
2022 Q4	$39.2K	Hold	1,568	–	–	﹤0.01%	3407
2022 Q3	$50K	Hold	1,568	–	–	﹤0.01%	3330
2022 Q2	$62K	Hold	1,568	–	–	﹤0.01%	3360
2022 Q1	$64K	Hold	1,568	–	–	﹤0.01%	3496
2021 Q4	$80K	Hold	1,568	–	–	﹤0.01%	3466
2021 Q3	$102K	Hold	1,568	–	–	﹤0.01%	3378
2021 Q2	$61K	Hold	1,568	–	–	﹤0.01%	3342
2021 Q1	$83K	Buy	1,568 +866	+123%	+$58.1K	﹤0.01%	3396
2020 Q4	$48K	Hold	702	–	–	﹤0.01%	3354
2020 Q3	$27K	Hold	702	–	–	﹤0.01%	3303
2020 Q2	$28K	Hold	702	–	–	﹤0.01%	3281
2020 Q1	$22K	Hold	702	–	–	﹤0.01%	3194
2019 Q4	$80K	Hold	702	–	–	﹤0.01%	3109
2019 Q3	$23K	Hold	702	–	–	﹤0.01%	3154
2019 Q2	$31K	Hold	702	–	–	﹤0.01%	3182
2019 Q1	$39K	Buy	+702	New	+$37.8K	﹤0.01%	3173
2018 Q2	–	Sell	-1,790	Closed	-$69K	–	3134
2018 Q1	$69K	Hold	1,790	–	–	﹤0.01%	3059
2017 Q4	$104K	Hold	1,790	–	–	﹤0.01%	3031
2017 Q3	$119K	Hold	1,790	–	–	﹤0.01%	3055
2017 Q2	$152K	Buy	+1,790	New	+$240K	﹤0.01%	3066

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Charles Schwab's MTNB Position: Q3 2023 in Review

Charles Schwab sold out of Matinas BioPharma (MTNB) in Q3 2023, closing a stake of 1,568 shares — an estimated $28.2K sold.

Charles Schwab first reported a position in MTNB in Q2 2017 and held it in 22 quarters. The position peaked at $152K in Q2 2017. 47 funds tracked by Wall St. Rank hold MTNB as of Q3 2023.

Charles Schwab reported no remaining Matinas BioPharma position as of Q3 2023 after selling out during the quarter.
Charles Schwab sold 1,568 Matinas BioPharma shares in Q3 2023, an estimated $28.2K.
Charles Schwab first reported a position in Matinas BioPharma in Q2 2017 and held it in 22 quarters.
Charles Schwab's Matinas BioPharma position peaked at $152K in Q2 2017.
47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.